KIF18A-IN-2 is an inhibitor of mitotic kinesin Kif18A with IC50 of 28 nM and can be used in studies about chromosomal instability-associated vulnerabilities.

Kif15-IN-1, a mitotic Kinesin family member 15 (Kif15) inhibitor, is utilized in the study of cellular proliferative diseases.

KIF18A-IN-1 is a potent inhibitor of the mitotic kinesin KIF18A. This compound demonstrates significant anti-tumor properties.

KIF18A-IN-4 is a moderately potent non-competitive KIF18A inhibitor of ATP and microtubule with an IC50 of 6.16 μM. KIF18A-IN-4 selectively acts on a large number of mitotic kinesins and kinases, with no direct effect on microtubule protein assembly. KIF18A-IN-4 shows anti-tumour effects.

KIF18A-IN-3 is a potent inhibitor of KIF18A with an IC50 value of 61 nM. KIF18A-IN-3 significantly causes mitotic arrest and increases the number of mitotic cells in tumour tissue. kIF18A-IN-3 can be used to study tumours.

KIF18A-IN-7 is an orally active inhibitor targeting KIF18A, demonstrating potent inhibition with an IC50 value of 9.4 nM against the microtubule-dependent ATPase activity of KIF18A.

HIF1-IN-3 (Benzenepropanamide, N-[(8-hydroxy-7-quinolinyl)(4-methoxyphenyl)methyl]-) is an effective inhibitor of HIF-1 (EC50 = 0.9 μM) and can be used in anticancer studies.

Kif15-IN-2 is used for the research of cellular proliferative diseases. Kif15-IN-2 is an inhibitor of the mitotic kinesin Kif15.

BTB06584 is an IF1-dependent, selective inhibitor of the mitochondrial F1 Fo-ATPase. BTB06584 is a novel acetohydroxyacid synthase(AHAS) inhibitor, a promising drug target against Mycobacterium tuberculosis (MTB).